Rigel Pharmaceuticals(RIGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 2.9 | EPS (ttm) | 16.32 | Insider Own | 3.35% | Shs Outstand | 18.6M | Perf Week | -4.33% |
| Market Cap | 0.88B | Forward P/E | 10.32 | EPS next Y | 33.56% | Insider Trans | -0.79% | Shs Float | 18.1M | Perf Month | 12.52% |
| Enterprise Value | 0.83B | PEG | - | EPS next Q | 0.92 | Inst Own | 88.59% | Short Float | 17.75% | Perf Quarter | 52.96% |
| Income | 0.32B | P/S | 3.19 | EPS this Y | -82.39% | Inst Trans | -9.35% | Short Ratio | 9.36 | Perf Half Y | 73.5% |
| Sales | 0.28B | P/B | 2.07 | EPS next 5Y | - | ROA | 88.46% | Short Interest | 3.20M | Perf YTD | 10.39% |
| Book/sh | 22.81 | P/C | 9.26 | EPS past 3/5Y | - | ROE | 126.9% | 52W High | -9.49% ($52.24) | Perf Year | 29.61% |
| Cash/sh | 5.1 | P/FCF | 11.12 | Sales past 3/5Y | 34.76% 22.06% | ROIC | 75.66% | 52W Low | 89.5% ($24.95) | Perf 3Y | 333.76% |
| Dividend Est. | - | EV/EBITDA | 9.23 | EPS Y/Y TTM | 221.64% | Gross Margin | 91.39% | Volatility(W/M) | 3.15% 3.93% | Perf 5Y | 22.17% |
| Dividend TTM | - | EV/Sales | 2.99 | Sales Y/Y TTM | 3.31% | Oper. Margin | 31.45% | ATR (14) | 1.75 | Perf 10Y | 43.71% |
| Dividend Ex-Date | - | Quick Ratio | 1.79 | EPS Q/Q | -73.08% | Profit Margin | 116.3% | RSI (14) | 60.25 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.94 | Sales Q/Q | -22.6% | SMA20 | 2.63% ($46.07) | Beta | 1.19 | Target Price | $63 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/4 | SMA50 | 11.61% ($42.36) | Rel Volume | 0.38 | Prev Close | $47.22 |
| Employees | 174 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 903.42% 42.39% | SMA200 | 29.76% ($36.44) | Avg Volume(3M) | 0.34M | Price | $47.28 |
| IPO | 2000/11/29 | Option/Short | Yes/Yes | Trades | 3517 | Volume | 130,875 | Change | 0.13% |
Company
RIGL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Rigel Pharmaceuticals (RIGL) is a U.S. commercial-stage biotech company that develops and markets small-molecule drugs targeting rare diseases such as immune and hematologic disorders and cancer. The company has secured a position in the spleen tyrosine kinase (Syk) inhibitor class and has established itself as a revenue-generating company with marketed products in chronic immune thrombocytopenia and acute myeloid leukemia.
Over the past 1 year, on the higher side
9% below its 1-year high.
RIGL makes money exceptionally well
31.45% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -82.4% this year.
Tap to view numbers
The stock looks undervalued
Trading at 2.9 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +333.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 88.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FDLS 0.01%
FDM 0.01%
IDNA 0.01%
AFSM 0.01%
BBC 0.01%It ranks #4 in the industry
Based on market cap of $883M.
RIGL $883M PER 2.9
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is RIGL?
RIGL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RIGL?
The market cap of RIGL is approximately $883M, ranking 2,741 within its sector.
What is the P/E ratio of RIGL?
RIGL has a P/E ratio of approximately 2.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RIGL?
RIGL has recorded a 52-week high of $52.24 and a low of $24.95.
